Brown adipose tissue, or BAT, is often described as the body’s biological furnace. Unlike white adipose tissue, which stores energy in the form of large lipid droplets, brown fat burns energy to generate heat, a process known as thermogenesis. This is accomplished largely through uncoupling protein 1, or UCP1, which short-circuits the mitochondrial proton gradient to release energy as heat rather than storing it as ATP. In humans, BAT activity declines with age and obesity, and reduced BAT function has been linked to impaired postprandial glucose clearance, meaning the body’s ability to handle blood sugar spikes after meals. This connection has fueled interest in BAT activation as a therapeutic target for metabolic disease.

The Zagreb team, led by Nikola Habek and Aleksandra Dugandžić, focused on uroguanylin, a peptide hormone that binds to guanylate cyclase C receptors and has previously been implicated in appetite regulation and gut-brain signaling. Uroguanylin is synthesized as an inactive precursor, proguanylin-like pro-uroguanylin (proUGN), which is then cleaved into its active form. While UGN’s role in the intestine is well characterized, its expression and function within the central nervous system, particularly in relation to thermoregulation, have remained poorly understood. The researchers set out to determine whether brain-derived UGN contributes to the regulation of BAT activity, and whether this contribution differs between the sexes.

To address this question, the team employed a multi-pronged experimental strategy. Brown adipose tissue activity was assessed using infrared thermography in wild-type C57Bl/6NCrl mice and UGN knockout littermates. BAT volume was measured using magnetic resonance imaging, while molecular markers associated with the “browning” of fat tissue were quantified using quantitative polymerase chain reaction. In parallel, the researchers measured proUGN expression in both mouse and human brain tissue using enzyme-linked immunosorbent assay, or ELISA. The inclusion of human tissue added a translational dimension often missing from preclinical metabolic studies.

One of the most striking findings emerged from the human brain analysis. In tissue obtained from human subjects, the researchers observed decreased proUGN expression in several brain regions, specifically the hypothalamus, Brodmann area 10, and Brodmann area 11, but only in male subjects with obesity. No comparable decrease was detected in female brain tissue. The hypothalamus is a well-established hub for autonomic control of BAT thermogenesis, receiving input from hunger and satiety circuits and sending sympathetic signals to brown fat depots via the spinal intermediolateral cell column. Brodmann areas 10 and 11, located in the prefrontal cortex, have been implicated in higher-order regulation of appetite and metabolic control. The male-specific reduction in proUGN in these regions suggests that obesity may disrupt a UGN-dependent pathway in a sexually dimorphic manner.

In mice, the relationship between feeding, brain UGN, and brown fat activation also proved to be sex-dependent. After a meal, brown adipose tissue normally increases its activity as part of diet-induced thermogenesis, helping to dissipate excess energy and support glucose disposal. The researchers found that this postprandial activation of BAT was linked to changes in hypothalamic proUGN expression, but this coupling was observed only in male mice. Female mice did not show the same pattern of hypothalamic proUGN regulation after eating, suggesting that the mechanism linking food intake to BAT activation through brain UGN operates differently, or possibly not at all, in females.

The role of the reproductive cycle added another layer of complexity. In female mice, the effects of centrally applied uroguanylin depended not only on sex but also on the phase of the estrous cycle. This finding is notable because it underscores a methodological concern that has gained increasing attention in neuroscience and metabolic research. Many laboratory studies, particularly those in rodents, historically used only male animals, partly to avoid variability attributed to the estrous cycle. The current study suggests that such variability is not mere noise but reflects genuine physiological regulation that could be clinically relevant for female patients.

The researchers also explored whether a GLP-1 analogue, a class of drugs that has transformed the treatment landscape for obesity and type 2 diabetes through medications such as semaglutide and liraglutide, could modulate brain UGN expression and BAT activity. In young male mice, intranasal administration of a GLP-1 analogue increased brown adipose tissue activity and decreased hypothalamic proUGN expression, but these effects were seen only in males. In both male and female mice, the GLP-1 analogue increased BAT activity, suggesting that GLP-1 receptor agonists engage thermogenic pathways through mechanisms that extend beyond UGN signaling, particularly in females. This observation points toward a completely different mechanism of GLP-1 action in the female brain and may help explain sex-dependent differences in clinical responses to these medications.

Chronic administration of uroguanylin itself produced another intriguing sex difference. When UGN was given repeatedly, postprandial BAT activation increased in both sexes, indicating that the hormone can indeed enhance brown fat thermogenic responses in males and females alike. However, an increase in total brown adipose tissue volume was observed only in male mice. Because BAT volume is a determinant of overall thermogenic and glucose-handling capacity, this finding implies that the long-term metabolic benefits of UGN-based interventions may be structurally different in males and females. In males, UGN appears capable of both activating existing brown fat and expanding the tissue itself, whereas in females, the effect appears limited to functional activation without tissue expansion.

The authors emphasize that the therapeutic implications of these findings are substantial. If brain-derived UGN regulates brown fat in a sex-dependent manner, then any attempt to harness this pathway for the treatment of obesity or type 2 diabetes must account for the patient’s sex. A UGN-based therapy that works well in men might produce blunted or entirely different effects in women, and vice versa. Similarly, the estrous-cycle dependence of UGN’s central effects in females raises the possibility that hormonal status, including menstrual cycle phase, hormonal contraceptive use, or menopause, could influence how women respond to BAT-targeting therapies. This kind of nuance has been historically overlooked in metabolic drug development, where clinical trials often enroll predominantly male participants or fail to stratify results by sex.

The study also raises fundamental questions about the biology of uroguanylin in the central nervous system. The finding that proUGN expression decreases in the hypothalamus and prefrontal cortex of men with obesity suggests that obesity may perturb a brain peptide system that is not typically considered part of the metabolic disease landscape. Whether this reduction is a cause or consequence of obesity, and whether it can be reversed through weight loss or pharmacological intervention, remains to be determined. The mouse data indicating that GLP-1 analogues can modulate hypothalamic proUGN expression adds an additional dimension, suggesting that some of the metabolic benefits of these blockbuster weight-loss drugs could be mediated, at least in part, through UGN-dependent pathways in males.

The Zagreb team’s work fits within a growing body of literature highlighting sex differences in metabolic physiology. Brown adipose tissue itself is known to differ between males and females in humans, with some studies suggesting higher BAT prevalence and activity in women. The neural circuits governing BAT thermogenesis, including hypothalamic and brainstem pathways, are also influenced by gonadal hormones such as estrogen and testosterone. By demonstrating that a specific brain peptide, uroguanylin, participates in this sexual dimorphism, the study provides a concrete molecular handle on a phenomenon that has long been recognized but poorly understood at the mechanistic level.

Looking ahead, the researchers suggest that the development of therapies targeting brain-activated brown fat must incorporate sex as a biological variable from the earliest stages of research and development. As the global burden of obesity and type 2 diabetes continues to grow, and as GLP-1 receptor agonists reshape expectations for pharmacological treatment, understanding the precise neural mechanisms through which these interventions work, and how they differ between men and women, will be critical for optimizing their use. The study by Habek, Ratko, Dugandžić, and colleagues represents an important step in that direction, revealing that one of the brain’s most overlooked peptides may play a central role in determining how our bodies burn the calories we consume.

Brown adipose tissue (BAT) is specialized for heat production through non-shivering thermogenesis, a process critically dependent on mitochondrial activity and calcium signaling. Unlike white adipocytes that store energy, brown adipocytes dissipate energy as heat, a function central to energy balance and metabolic health. While the role of calcium in BAT thermogenesis is increasingly recognized, the specific molecular players orchestrating calcium signaling within brown fat cells remained obscure until now. This study decisively positions HuR as a crucial regulator of RyR2 expression, the calcium-release channel integral to triggering thermogenic processes.

The ryanodine receptor family consists of intracellular calcium channels that facilitate rapid calcium release from the endoplasmic reticulum, serving as a key signal for cellular bioenergetics adjustments. RyR2, traditionally studied in cardiac muscle for its control over excitation-contraction coupling, is now identified as indispensable in the thermogenic function of brown fat cells. Researchers demonstrated that HuR binds to the mRNA of RyR2, stabilizing it to maintain adequate receptor levels necessary for proper calcium mobilization.

Experimental data derived from murine models showed that the deficiency or suppression of HuR leads to a marked decrease in RyR2 expression within brown adipocytes. This downregulation impairs calcium release, leading to diminished thermogenic capacity and lower mitochondrial respiration rates. Intriguingly, reintroducing HuR or enhancing its activity restored RyR2 levels and subsequent heat generation, establishing a direct causal link between HuR-mediated mRNA stability and thermogenesis.

This molecular axis is critical because calcium flux within brown adipocytes triggers uncoupling protein 1 (UCP1) activation, a mitochondrial protein responsible for dissipating the proton gradient to produce heat instead of ATP. The study elucidates that without sufficient RyR2-mediated calcium release, UCP1 activity declines significantly, resulting in inefficient thermogenic response. Thus, HuR and RyR2 together form an essential regulatory checkpoint for efficient cellular thermogenesis.

Beyond fundamental biology, this research harbors profound therapeutic implications. Obesity arises from an imbalance between energy intake and expenditure. Enhancing brown adipose tissue thermogenesis is a promising strategy to increase caloric burn and improve metabolic health. By pinpointing HuR as a target to modulate RyR2 levels, future drug development may harness this pathway to stimulate endogenous heat production, offering a novel approach to weight management and treatment of metabolic diseases such as type 2 diabetes.

Additionally, the study employed sophisticated molecular biology techniques including RNA immunoprecipitation and real-time quantitative PCR to validate the interaction between HuR and RyR2 mRNA. Advanced imaging approaches captured dynamic calcium transients within brown adipocytes, corroborating the functional consequences of HuR depletion. This multi-layered methodological strategy strengthens the validity and translatability of the findings.

Thermogenesis in brown adipose tissue is a complex, multifaceted process governed by numerous signaling networks. This research importantly highlights the post-transcriptional regulatory layer, shaped by RNA-binding proteins, in fine-tuning gene expression related to energy metabolism. It underscores the emerging paradigm that RNA dynamics are crucial determinants in adaptive thermal physiology.

Future studies are anticipated to explore whether HuR-dependent control of RyR2 exists in human brown adipose tissue and how this pathway might vary across different physiological or pathological states. A deeper understanding could illuminate personalized strategies to harness endogenous thermogenesis tailored for individual metabolic profiles.

Moreover, the identification of HuR as a regulatory hub invites exploration into its interactions with other thermogenic factors, potentially revealing an intricate regulatory nexus overseeing energy dissipation. Understanding these connections could foster comprehensive therapeutic models targeting multiple nodes within the thermogenic network.

The application of these findings extends beyond obesity to conditions involving impaired mitochondrial function or altered calcium signaling. For example, metabolic syndromes and cardiovascular diseases may benefit from therapeutics modulating HuR or RyR2 activity, given their broad roles in cellular homeostasis.

Importantly, this study challenges existing dogma that primarily attributes thermogenic regulation to transcriptional control by nuclear receptors and transcription factors, presenting post-transcriptional modulation as a critical complementary mechanism. The precise balancing of mRNA stability ensures rapid and flexible thermogenic responses to environmental or metabolic demands.

In summary, the research by Guarnieri and colleagues represents a pivotal advance in our comprehension of thermogenesis, emphasizing the HuR-RyR2 axis as an indispensable component of calcium-mediated energy expenditure in murine brown adipocytes. Its implications resonate across physiology and medicine, holding tantalizing prospects for novel interventions against metabolic diseases. As global health confronts rising obesity rates, such insights provide hope for innovative and efficacious metabolic therapies rooted in molecular precision.

The convergence of cellular physiology, molecular biology, and metabolic science within this study exemplifies the future of biomedical research—where dissecting intricate molecular interactions translates into tangible clinical benefits. This compelling contribution to the field illuminates a new path forward in our quest to understand and manipulate the body’s natural energy regulation mechanisms.

Subject of Research: The molecular mechanisms regulating calcium-mediated thermogenesis in murine brown adipocytes, focusing on HuR-dependent expression of ryanodine receptor 2 (RyR2).

Article Title: HuR-dependent expression of RyR2 contributes to calcium-mediated thermogenesis in murine brown adipocytes.

Article References:
Guarnieri, A.R., Anthony, S.R., Wen, BY. et al. HuR-dependent expression of RyR2 contributes to calcium-mediated thermogenesis in murine brown adipocytes. Sci Rep (2026). https://doi.org/10.1038/s41598-026-54659-x

Image Credits: AI Generated

Brown adipose tissue, unlike its white counterpart, is specialized for generating heat through non-shivering thermogenesis, a process critical for maintaining body temperature and metabolic health. Central to this function is the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ), a transcription factor extensively studied for its role in adipocyte differentiation and lipid metabolism. However, this new research highlights an unexpected regulatory layer wherein PPARγ’s activity is modulated by a novel post-translational modification, specifically HMGylation—a modification involving the addition of a hydroxy-methylglutaryl group—which has not been previously linked to BAT physiology.

At the heart of this mechanism is AUH (AU RNA-binding protein/enoyl-CoA hydratase), an enzyme traditionally appreciated for catalyzing a key step in leucine catabolism. The enzyme’s ability to catalyze the conversion of methylglutaconyl-CoA to 3-hydroxy-3-methylglutaryl-CoA, a vital intermediate in leucine metabolism, was well documented, yet this study reveals a bifunctional role. Besides enzymatic catalysis, AUH exerts a RNA-binding function that appears to modulate thermogenic gene expression at a post-transcriptional level, suggesting that AUH acts as a metabolic sensor linking amino acid catabolism to thermogenic control.

The researchers utilized a combination of advanced proteomics, transcriptomics, and metabolic phenotyping to demonstrate that in male mice, loss of AUH dampens BAT thermogenesis and decreases energy expenditure, leading to increased adiposity and impaired glucose homeostasis. Mechanistically, AUH facilitates the HMGylation of PPARγ, which augments its transcriptional activity, thereby enhancing the expression of thermogenic genes such as Ucp1. This post-translational modification represents a previously unrecognized mode of fine-tuning PPARγ function in the context of energy metabolism.

Moreover, the RNA-binding aspect of AUH adds a new dimension to thermogenic regulation. The study shows that AUH interacts with specific RNA transcripts in BAT, which likely influences their stability and translation. This dual enzymatic and RNA-binding capability allows AUH to coordinate metabolic inputs from leucine catabolism with gene networks responsible for heat production, effectively coupling nutrient status with energy expenditure.

Another striking element of the study is the sex-specific nature of AUH’s function. The authors report that the regulatory axis involving AUH, PPARγ HMGylation, and RNA-binding predominantly impacts male mice, underscoring complex sexual dimorphisms in BAT biology. This raises exciting questions about how metabolic pathways diverge between sexes and suggests that AUH-targeted therapies might require sex-specific considerations.

This discovery could radically enhance our understanding of the multifaceted control of energy balance, as BAT has been recognized as a promising target for combating metabolic diseases due to its ability to dissipate excess calories as heat. By revealing that an amino acid catabolic enzyme interacts integratively with nuclear receptor signaling and RNA biology, the study broadens the scope of metabolic regulation beyond classical pathways, suggesting new therapeutic targets that capitalize on multifunctional protein enzymes like AUH.

The methodology employed by Jiang and colleagues is equally noteworthy. They combined genetic manipulation techniques, including BAT-specific AUH knockout and overexpression models, with sophisticated mass spectrometry assays capable of detecting PTMs like HMGylation in situ. This allowed for precise mapping of modification sites on PPARγ and assessment of the functional consequences on transcriptional activity. Concurrent RNA immunoprecipitation and sequencing helped delineate AUH’s RNA interaction partners, unveiling a complex post-transcriptional regulatory network.

In addition to the molecular and cellular insights, the physiological assessments confirmed the systemic impacts of AUH modulation. Male mice deficient in AUH exhibited reduced cold tolerance and diminished whole-body energy expenditure, aligning molecular observations with organismal phenotypes. These systemic manifestations underscore the enzyme’s critical role in maintaining metabolic health.

The link between leucine metabolism and thermogenic regulation through AUH also suggests an intriguing metabolic feedback loop. Leucine, a branched-chain amino acid, is an essential nutrient with known effects on mTOR signaling and metabolic health. The coupling of its catabolism to BAT function via AUH implies that dietary and metabolic states could directly influence thermogenic capacity, positioning AUH as a metabolic rheostat that senses nutrient flux and calibrates energy dissipation accordingly.

Furthermore, this research prompts a reevaluation of the functional repertoire of PTMs in nuclear receptor biology. While phosphorylation, acetylation, and ubiquitination of PPARγ have been extensively studied, the identification of HMGylation introduces a new biochemical layer that may have broader implications across different nuclear receptors and transcription factors with pivotal roles in metabolic control.

From a translational perspective, the multifaceted role of AUH holds promise for innovative intervention strategies. Targeting the enzymatic activity or the RNA-binding function of AUH could selectively modulate BAT thermogenesis, offering novel approaches to enhance energy expenditure without the side effects associated with global PPARγ agonists traditionally used in diabetes treatment.

Moreover, the sex-specific findings highlight the importance of personalized medicine in metabolic disease management. Future studies could investigate whether variations in AUH activity contribute to sex-related differences in metabolic disease prevalence and response to therapy, potentially leading to tailored treatments for men and women.

The data also invite closer scrutiny into the role of RNA-binding proteins in metabolism, an emerging field bridging RNA biology with metabolic regulation. AUH exemplifies how multi-domain proteins integrate metabolic cues with gene regulation, potentially inspiring the search for similar multifunctional enzymes in other metabolic tissues.

As exciting as these findings are, the research community must now explore the detailed molecular mechanisms governing AUH’s dual functions and their integration under physiological and pathological states. Questions remain about how HMGylation is dynamically regulated, the spectrum of RNA targets for AUH in BAT and perhaps other tissues, and whether similar mechanisms exist in humans.

In conclusion, the discovery that AUH regulates brown adipose tissue thermogenesis via PPARγ HMGylation and RNA-binding function represents a significant stride forward in metabolic research. It illuminates a nuanced biochemical nexus linking amino acid catabolism to energy expenditure, expanding our grasp of how the body maintains its thermal and metabolic balance. This integrative mechanism not only enhances fundamental understanding but also lays the groundwork for novel therapeutic strategies targeting metabolic diseases through modulation of multifunctional enzymes like AUH.

Subject of Research: Regulation of brown adipose tissue thermogenesis by the leucine catabolic enzyme AUH through PPARγ HMGylation and RNA-binding in male mice.

Article Title: Leucine catabolic enzyme AUH regulates BAT thermogenesis via PPARγ HMGylation and RNA-binding function in male mice.

Article References: Jiang, H., Ni, S., Li, Z. et al. Leucine catabolic enzyme AUH regulates BAT thermogenesis via PPARγ HMGylation and RNA-binding function in male mice. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71581-y

Image Credits: AI Generated

Brown adipose tissue (BAT) is well known for its ability to generate heat by burning calories, a process termed non-shivering thermogenesis. This is particularly essential during cold exposure, where BAT activation can help maintain body temperature. In contrast, beige fat—a type of fat that can convert white fat to a more metabolically active state—emerges as an important player in energy expenditure. Both types of fat possess unique characteristics that, while functionally similar in some respects, diverge significantly when influenced by hormonal levels. The review underscores that sex hormones such as estrogen and testosterone significantly impact the distribution, activity, and even formation of these adipose tissues. This suggests that men and women may have different metabolic responses based on their hormonal milieu.

A prominent theme in the literature is how estrogen influences the functioning of brown and beige fat. Research points towards estrogen’s role in promoting the development of brown adipocytes from precursor cells. Women, particularly in their reproductive years, exhibit higher levels of estrogen which may enhance the ability of brown and beige fat to induce thermogenesis. This could account for the protective effects against certain metabolic disorders often observed in premenopausal women. Conversely, with the reduction of estrogen levels during menopause, a noticeable decline in brown fat activation also occurs, which might contribute to the increased susceptibility to weight gain and metabolic disorders in older women.

Another layer of complexity arises when considering how body composition influences the functionality of brown and beige fat. Men and women emphasize different strategies for storing fat. Typically, men accumulate more visceral fat, which is known to correlate with metabolic risk factors, while women tend to store subcutaneous fat, especially in the hips and thighs. This distinction is vital, as it implies different health risks associated with fat accumulation patterns, mediated by hormonal influences. The review brings to light how these differences may not only reflect underlying genetic factors but also be driven by environmental and lifestyle factors, which further complicate our understanding of sex-based differences in fat physiology.

As the research unfolds, the implications for obesity treatments specific to sexual orientation emerge, emphasizing the necessity of a personalized approach when addressing metabolic health. An understanding of the intricate relationship between sex hormones and fat biology could pave the way for innovative therapies tailored to an individual’s hormonal status. Traditional weight-loss strategies that fail to consider sex differences may not only be ineffective but could lead to differential health outcomes based on the individual’s biological sex.

Furthermore, this review draws attention to how environmental stressors like temperature can modulate the physiological behaviors of brown and beige fat. Exposure to cold has been shown to activate thermogenesis through various pathways, including the sympathetic nervous system and hormonal changes. Notably, the response to cold exposure may vary substantially between sexes due to inherent physiological differences. As males and females respond differently to thermal stress, their capabilities for heat production can diverge, leading to distinct metabolic responses in relation to fat utilization during energy expenditure.

Moreover, the researchers emphasize a need for more interdisciplinary approaches that unite endocrinology, metabolism, and gender studies to improve our understanding of how lifestyle interventions, diet, and physical activity can be tailored to exploit these sex-based differences. This could facilitate the development of more effective metabolic health strategies that consider the interplay of hormonal, genetic, and lifestyle factors. Acknowledging that one-size-fits-all approaches may be outdated in the face of sex-differentiated biology is paramount in contemporary scientific discourse.

Another point raised in the review is the potential for technology and innovation to drive further research in this field. Advances in imaging techniques and molecular biology tools have enhanced our ability to observe and manipulate brown and beige fat biology at unprecedented levels of detail. These tools can enable researchers to dissect the molecular mechanisms behind sex differences in fat biology, revealing novel targets for therapeutic intervention. Improved biological understanding could also lead to the discovery of pharmacological agents that mimic the effects of hormone treatment on fat metabolism, refining obesity and metabolic syndrome treatment options.

In conclusion, the work by Shashank et al. lays a foundational understanding of the biological interplay between hormones, temperature, and sex differences in brown and beige fat. As this frontier of research progresses, it cultivates a crucial dialogue about sex-specific healthcare tailored to physiological complexities. Emphasizing the role of sex in metabolic functions not only addresses health inequities but enhances our collective understanding of energy metabolism. Ultimately, as we contemplate the future of obesity and metabolic disorders, it is clear that a nuanced recognition of sex-based differences will be essential for devising effective interventions.

The ongoing exploration of brown and beige fat biology opens doors to novel understanding regarding metabolic health. With continuous research and collaboration across disciplines, the healthcare field is likely to see transformative improvements in treatment protocols, which could vastly influence the prevention and management of obesity and its associated risks. As scientists and clinicians work hand in hand, the integration of sex-based considerations in research could illuminate pathways toward better patient outcomes and wellness, signifying a monumental shift in our approach to health.

Subject of Research: Sex-based differences in brown and beige fat biology.

Article Title: Hormones, heat, and health: a comprehensive review of sex-based differences in brown and beige fat biology.

Article References:

Shashank, C.G., Mandali, R. & Wankhade, U.D. Hormones, heat, and health: a comprehensive review of sex-based differences in brown and beige fat biology.
Biol Sex Differ (2025). https://doi.org/10.1186/s13293-025-00787-4

Image Credits: AI Generated

DOI:

Keywords: Brown fat, beige fat, sex differences, hormones, thermogenesis, metabolism, obesity, health.

Obesity remains a pervasive global health challenge, intimately linked with metabolic disorders such as type 2 diabetes and cardiovascular diseases. Epidemiological data have consistently shown that despite similar or higher rates of obesity, women tend to have a lower incidence of obesity-associated diabetes and cardiovascular complications compared to men. This disparity has long suggested inherent biological differences modulating metabolic health, yet the molecular underpinnings have been obscure. Brown adipose tissue, a highly specialized fat depot responsible for non-shivering thermogenesis and energy dissipation, emerges as a crucial player given its known higher activity levels in females relative to males.

The research team, comprising experts from the Institute of Science Tokyo and the University of Tokyo, leveraged genetically engineered mouse models to dissect the role of PGC-1α specifically in brown fat cells. This protein has been widely recognized as a master regulator of mitochondrial biogenesis and energy metabolism across multiple tissues; however, its sex-specific function in BAT had remained uncharted territory. By selectively deleting the PGC-1α gene in brown fat tissue, the investigators observed a striking phenotype wherein female mice exhibited impaired thermogenesis, diminished oxygen consumption, and altered mitochondrial ultrastructure, while male counterparts showed negligible effects.

Multi-omics approaches—encompassing transcriptomic, metabolomic, and lipidomic analyses—were instrumental in delineating the molecular landscape altered by PGC-1α deficiency. Transcriptomic profiling revealed downregulation of genes implicated in de novo lipogenesis (DNL), particularly those governed by ChREBPβ (Carbohydrate-response element-binding protein beta), a known transcriptional activator of lipogenic pathways. This downregulation bore profound metabolic consequences, as lipidomic analyses demonstrated a significant reduction in critical phospholipid species such as ether-linked phosphatidylethanolamine and cardiolipin. These phospholipids are vital components of the mitochondrial inner membrane, essential for maintaining mitochondrial structural integrity and optimizing electron transport chain function.

The attenuation of phospholipid synthesis triggered cascading mitochondrial dysfunction specifically in female BAT. Electron microscopy disclosed disrupted mitochondrial cristae architecture and reduced cristae density, which correlate with compromised oxidative phosphorylation efficiency. Functionally, this mitochondrial impairment manifested as lower heat production and decreased systemic energy expenditure. The male mice maintained more intact mitochondrial morphology and function, indicating that the PGC-1α-dependent lipid synthesis pathway is critically active and indispensable for female BAT thermogenesis but operates differently or less stringently in males.

Intriguingly, the study further elucidated the hormonal regulation that enhances this pathway in females. Estrogen signaling was shown to amplify the expression of PGC-1α and downstream lipogenic genes, thereby potentiating the lipid synthesis machinery and mitochondrial robustness in female brown fat. This synergy between PGC-1α and estrogen provides a mechanistic basis for the observed superior thermogenic capacity in females, linking sex hormones directly to metabolic programming in BAT.

To corroborate the centrality of ChREBPβ in this cascade, the researchers conducted targeted suppression of ChREBPβ in female mice, which phenocopied the mitochondrial disruptions and reduced thermogenesis seen with PGC-1α deletion. This not only confirms ChREBPβ as a pivotal effector downstream of PGC-1α but also rules out off-target effects, thereby sharpening the mechanistic clarity. The lack of similar effects in males upon ChREBPβ suppression reiterates the sex-specific nature of this regulatory axis.

Taken together, these findings unveil a female-specific metabolic pathway wherein PGC-1α orchestrates phospholipid biosynthesis via ChREBPβ, synergized by estrogen, culminating in fortified mitochondrial architecture and elevated brown fat thermogenic function. This pathway represents an evolutionarily conserved mechanism potentially designed to meet the greater metabolic demands and thermal regulation needs in females, thereby contributing to observed sex differences in metabolic disease susceptibility.

The implications for biomedical science and therapeutic development are profound. By targeting the PGC-1α–ChREBPβ lipid synthesis axis, it may be possible to selectively enhance brown fat activity and mitochondrial function, thereby boosting energy expenditure and ameliorating metabolic diseases such as obesity and diabetes. This sex-specific strategy promises to tailor interventions that respect biological differences, enhancing efficacy and reducing adverse effects.

Furthermore, the elucidation of estrogen’s role in amplifying this metabolic axis underscores the importance of considering hormonal milieu in understanding metabolic health and disease. Future studies may continue to explore the dynamic interplay between sex hormones, transcriptional regulators, and lipid metabolism across diverse tissues and physiological states.

This research not only clarifies a longstanding biological enigma behind sex differences in energy metabolism but also exemplifies the power of integrative multi-omics combined with sophisticated genetic models to uncover intricate physiological pathways. As obesity and metabolic disorders continue to challenge global health, such mechanistic revelations pave the way for precision medicine approaches that harness the body’s own metabolic regulatory systems.

By expanding our molecular understanding of BAT functionality and its regulation by sex-specific factors, this study ignites new scientific inquiries and translational opportunities. The prospect of leveraging brown fat thermogenesis to combat metabolic dysfunction holds immense promise, with PGC-1α-mediated phospholipid synthesis now emerging as a central target illuminated by this pioneering work.

Subject of Research: Animals

Article Title: Sex difference in BAT thermogenesis depends on PGC-1α–mediated phospholipid synthesis in mice

News Publication Date: 14-Jul-2025

Web References:
https://doi.org/10.1038/s41467-025-61219-w

Image Credits: Institute of Science Tokyo

Keywords: Obesity, Metabolic disorders, Diseases and disorders, Health and medicine, Diabetes

Brown adipose tissue (BAT) has been revered within the scientific community for its thermogenic prowess, enabling mammals to dissipate energy as heat, thereby contributing to energy balance and protection against obesity. Unlike white adipose tissue, which primarily stores energy in the form of lipids, BAT contains densely packed mitochondria and specialized uncoupling proteins, granting it the unique ability to burn calories. However, the plasticity of brown adipocytes, especially under pathological or stressed states marked by mitochondrial compromise, remains a critical enigma. The present work reveals how mitochondrial dysfunction triggers a cascade culminating in the accumulation of 2-hydroxyglutarate (2-HG), a metabolite that orchestrates the phenotypic transformation of brown adipocytes.

At the heart of this cellular reprogramming lies the mitochondrial failure that disrupts the tricarboxylic acid (TCA) cycle and associated bioenergetics. Mitochondria, beyond their classical role in ATP production, generate a myriad of metabolites that function as signaling molecules and epigenetic regulators. When mitochondrial integrity falters, the resultant metabolic imbalance leads to the abnormal elevation of 2-HG, a metabolite normally present at trace levels. Elevated 2-HG has been extensively studied in cancer contexts, especially gliomas and leukemias carrying mutations in isocitrate dehydrogenase (IDH) enzymes. Yet, its role in adipocyte biology and systemic metabolism had been elusive until now.

The authors employed a combination of cutting-edge metabolomic profiling, super-resolution microscopy, and biophysical assessments to unravel how 2-HG orchestrates its effects at the interface of cellular metabolism and nuclear structure. Mitochondrial defects induced pharmacologically or genetically elevated intracellular 2-HG, which in turn initiated a process akin to the “whitening” phenomenon, where brown adipocytes lose their thermogenic identity and acquire white fat-like characteristics. This conversion is strikingly coupled with a measurable softening of the nuclear envelope, a biophysical change with extensive ramifications for gene expression and chromatin organization.

Investigation into the nuclear mechanical properties revealed that mitochondrial distress impacts lamin A/C and other nuclear structural proteins, altering nuclear stiffness. This softening correlates with epigenetic remodeling, likely mediated through 2-HG-dependent inhibition of α-ketoglutarate-dependent dioxygenases, including histone and DNA demethylases. These epigenetic enzymes are known to be exquisitely sensitive to metabolic cues, and their inhibition manifests as altered chromatin accessibility and transcriptional rewiring. Thus, mitochondrial health not only governs cellular metabolism but also directly signals to chromatin architecture, dictating cellular fate and function.

The whitening of brown adipocytes diminishes their capacity for heat generation, with profound implications for systemic metabolism, particularly in energy expenditure and insulin sensitivity. This newly uncovered axis raises tantalizing questions about the role of mitochondrial metabolites as systemic signaling entities governing adipose tissue plasticity and metabolic health. Could the dysregulation of mitochondrial function and consequent metabolite shifts be a previously underappreciated driver of metabolic diseases such as obesity and type 2 diabetes? These findings suggest that restoring mitochondrial function or targeting 2-HG accumulation might reverse the detrimental white-like phenotype in BAT, opening new avenues for therapeutic intervention.

Beyond metabolism, the study pioneers a conceptual advance by directly linking mitochondrial metabolic pathology to changes in nuclear mechanical properties – a frontier previously explored mainly within the context of aging and disease. The nuclear envelope’s mechanical landscape emerges as a critical integrator of metabolic inputs, converting mitochondrial signals into structural and functional nuclear adjustments. The authors meticulously demonstrate that 2-HG accumulation leads to the downregulation of nuclear stiffness, altering mechanotransduction pathways and potentially modifying the cell’s response to environmental stress.

Methodologically, the integration of atomic force microscopy and live-cell imaging allowed the authors to quantify nuclear stiffness with exceptional precision, correlating these measurements with real-time metabolite fluxes. This interdisciplinary approach underscores the necessity of combining biophysical and biochemical methods to decipher the complexity of intracellular signaling networks. Moreover, the employment of brown adipocyte-specific mitochondrial manipulation models solidifies the causal link between mitochondrial dysfunction, 2-HG accumulation, and adipocyte phenotypic shifts, moving beyond mere correlation.

From a translational standpoint, these insights could revolutionize strategies to manipulate brown fat activity in metabolic disorders. Current approaches to activate BAT thermogenesis primarily focus on adrenergic signaling; however, this study suggests targeting mitochondrial metabolic pathways and metabolite signaling as a promising alternative. By preventing mitochondrial dysfunction or scavenging 2-HG, it may be possible to preserve or restore the thermogenic phenotype of BAT, enhancing whole-body energy expenditure and metabolic health.

Furthermore, the intriguing crosstalk between mitochondria and nuclear mechanics invites exploration of similar mechanisms in other cell types where mitochondrial impairment is central, such as neurons in neurodegenerative diseases or cardiomyocytes in heart failure. The concept that mitochondrial metabolites dynamically remodel nuclear architecture could be a unifying theme driving diverse pathophysiological processes.

The study also touches upon the potential impact of these findings on our understanding of aging. Mitochondrial decline is a hallmark of aging, and nuclear mechanical integrity is compromised in aged cells. The demonstration that mitochondrial metabolites directly modulate nuclear mechanics could thus provide a mechanistic underpinning for age-related functional decline in adipose tissue and other organs. Interventions aimed at maintaining mitochondrial function might therefore have far-reaching anti-aging effects beyond energy metabolism.

Importantly, the reported phenomenon of nuclear softening is reversible, as indicated in experiments where restoration of mitochondrial function normalized nuclear stiffness and reestablished brown adipocyte identity. This reversibility highlights the plastic nature of the nuclear-cytoplasmic axis and offers hope that metabolic and structural cellular derangements are not irrevocably fixed, but amenable to therapeutic modulation.

This study also redefines 2-hydroxyglutarate beyond its traditional role as an oncometabolite. By establishing 2-HG as a metabolite with broad influence over cellular identity, energy metabolism, and nuclear mechanics, it triggers a paradigm shift that will catalyze future research into the diverse roles of metabolic intermediates as multi-dimensional regulators of cell fate.

In conclusion, the work by Kaul, Isermann, Senft, and colleagues delivers a transformative perspective into how mitochondrial dysfunction propagates metabolic and structural reprogramming of brown adipocytes. By positioning 2-hydroxyglutarate as a pivotal mediator linking mitochondrial metabolism to nuclear softening and adipocyte whitening, this research opens up vast new territories for investigation with implications spanning metabolism, epigenetics, mechanobiology, and potential clinical translation. As the fields of cellular metabolism and nuclear biomechanics converge, the implications for understanding and treating metabolic diseases, aging, and beyond could be profound and far-reaching.

Subject of Research: Mitochondrial dysfunction-induced 2-hydroxyglutarate accumulation drives whitening of brown adipocytes linked to nuclear softening.

Article Title: 2-hydroxyglutarate mediates whitening of brown adipocytes coupled to nuclear softening upon mitochondrial dysfunction.

Article References:
Kaul, H., Isermann, L., Senft, K. et al. 2-hydroxyglutarate mediates whitening of brown adipocytes coupled to nuclear softening upon mitochondrial dysfunction. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01332-8

Image Credits: AI Generated

The liver, a central hub for glycolipid metabolism, governs energy distribution by finely tuning processes such as gluconeogenesis, lipogenesis, and lipid oxidation. Parallelly, brown adipose tissue, famed for its thermogenic capacity via uncoupling protein 1 (UCP1), dissipates energy as heat, thus contributing significantly to whole-body energy expenditure. Understanding the endocrine and molecular dialogue between these two organs has become paramount to unlocking new strategies against metabolic diseases aggravated by obesity.

Emerging evidence underscores the efficacy of naturally occurring bioactive compounds in modulating liver-BAT crosstalk. Polyphenols, alkaloids, and terpenoids—distinct classes of plant-derived molecules—appear to engage key signaling pathways that mediate metabolic flexibility. Compounds such as resveratrol and curcumin (polyphenols), berberine (alkaloid), and paeoniflorin and shikonin (terpenoids) have demonstrated promising capacity to activate adenosine monophosphate-activated protein kinase (AMPK), influence peroxisome proliferator-activated receptor (PPAR) pathways, and enhance UCP1-mediated thermogenesis in BAT.

Mechanistically, these bioactive agents facilitate a reduction in hepatic lipogenesis and gluconeogenic flux, thereby lowering circulating glucose and lipid levels. Concurrently, by stimulating BAT thermogenesis and promoting lipid oxidation, they augment energy expenditure. This dual action addresses the pathogenic hallmarks of obesity and insulin resistance, highlighting a sophisticated pharmacological potential embedded in natural compounds.

Moreover, the interplay involves hepatokines—liver-derived secretory proteins such as fibroblast growth factor 21 (FGF21)—and batokines, which serve as endocrine signals coordinating systemic metabolic adaptations. Natural bioactives appear to modulate the secretion and activity of these mediators, effectively fine-tuning interorgan communication essential for maintaining energy homeostasis.

Clinical and preclinical investigations have started to unravel how these compounds translate into tangible metabolic benefits. Rodent studies reveal improved insulin sensitivity and reduced adiposity upon administration of these natural agents, while emerging human data from nutraceutical interventions suggest potential for adjunctive therapy. Nonetheless, challenges remain, particularly in elucidating precise mechanisms, determining effective dosing, and addressing interindividual variability.

One area of intensified research focuses on AMPK, often dubbed the “metabolic master switch.” Activation of AMPK within hepatocytes and brown adipocytes initiates catabolic pathways that suppress fat accumulation and promote energy dissipation. Natural polyphenols, through direct or indirect modulation of AMPK, initiate cascades that alleviate lipotoxicity and enhance glucose uptake, representing a critical nexus for therapeutic exploitation.

In parallel, PPARs, nuclear hormone receptors integral to lipid metabolism and adipogenesis, emerge as targets modulated by these natural compounds. The ability to fine-tune PPAR signaling holds promise in recalibrating metabolic flexibility, particularly shifting energy usage towards fatty acid oxidation. This shift is essential for combating hepatic steatosis and improving insulin responsiveness in peripheral tissues.

The thermogenic prowess of BAT, driven predominantly by UCP1, represents a metabolic sink capable of substantial energy expenditure. Encouragingly, compounds such as berberine and paeoniflorin have been observed to upregulate UCP1 expression, thereby potentiating BAT activity. This activation counters obesity by increasing basal metabolic rate, positioning BAT as a therapeutic target not only for weight management but also for glucose homeostasis.

Understanding hepatokine and batokine signaling provides new molecular insights into how liver and BAT co-regulate systemic metabolism. FGF21, a hepatokine extensively studied for its metabolic effects, is augmented by certain natural bioactives, enhancing glucose disposal and lipid oxidation. Similarly, batokines secreted by activated BAT modulate liver function, closing a feedback loop that maintains equilibrium.

Despite promising data, translating these findings into clinical practice requires addressing several hurdles. Dose optimization, long-term safety, and understanding individual metabolic responses are critical areas needing comprehensive research. Personalized nutrition strategies integrating natural bioactives could offer tailored therapeutic modalities, optimizing efficacy while minimizing adverse effects.

Furthermore, the integration of nutraceuticals into lifestyle interventions amplifies their potential. When combined with diet and physical activity, these natural compounds may synergistically restore metabolic homeostasis. This multidimensional approach aligns with precision medicine paradigms and could revolutionize management practices for obesity-linked disorders.

In summary, the endocrine regulation of metabolic crosstalk between the liver and brown adipose tissue by natural bioactive compounds delineates a promising frontier in metabolic research. The convergence of molecular biology, pharmacology, and nutrition sciences is unveiling novel mechanisms to harness these substances in combatting the global burden of obesity and metabolic diseases.

As awareness of these natural modulators grows, they may soon become integral components of holistic metabolic health strategies, offering hope for millions struggling with obesity-related complications. Continued interdisciplinary efforts are warranted to fully decode their potential and develop evidence-based applications that transcend traditional pharmacotherapy.

This burgeoning field, at the interface of natural product chemistry and metabolic physiology, exemplifies how ancient botanical wisdom intersects with cutting-edge science, propelling us toward innovative and sustainable solutions for some of today’s most pressing health crises.

Subject of Research:

Article Title:

Article References:
Chen, QC., Cai, WF., Ni, Q. et al. Endocrine regulation of metabolic crosstalk between liver and brown adipose tissue by natural active ingredients. Int J Obes (2025). https://doi.org/10.1038/s41366-025-01793-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41366-025-01793-7

Keywords

For decades, scientists have known that lactation is marked by profound hormonal shifts, including a steep decline in circulating E2 levels coupled with a pronounced surge in PRL. These concurrent fluctuations are responsible for the mother’s physiological shift toward enhanced food intake and reduced energy expenditure through BAT thermogenesis suppression. Yet, the precise neural substrates by which these hormonal waves induce such dramatic changes in behavior and metabolism remained elusive until now. A team led by Yu, Feng, and Bean delved deeply into these mechanisms by focusing on the estrogen receptor alpha (ERα)-expressing neurons located in the medial basal hypothalamus (MBH)—a critical brain region responsible for integrating hormonal signals with metabolic control.

Their study highlights two main anatomical loci: the arcuate nucleus and the ventrolateral subdivision of the ventromedial hypothalamus (vlVMH). Both are rich in ERα-expressing neurons known to mediate the effects of E2 on feeding behavior and energy balance. What is particularly striking is that during lactation—when E2 levels plummet—these ERα^vlVMH neurons are significantly suppressed. This suppression seems to lift the inhibitory effects that E2 ordinarily exerts on PRL production and BAT thermogenesis, effectively reshaping the mother’s metabolic landscape to meet the increased energetic demands of nursing.

By employing genetically engineered mouse models, the researchers were able to dissect the causal role of ERα in these processes. When ERα was selectively deleted from MBH neurons in virgin female mice—animals that had not undergone the metabolic transformations of pregnancy and lactation—these mice spontaneously developed phenotypes remarkably similar to those seen in lactating mothers. They exhibited hyperprolactinemia, increased food intake, and diminished BAT thermogenesis. This key observation underscores the pivotal role of ERα in restraining prolactin levels and maintaining energy homeostasis under non-lactating conditions. It lends strong support to the hypothesis that the decline of E2 signaling during lactation is not just a passive occurrence but an active regulatory switch that facilitates maternal metabolic adaptation.

Conversely, the activation of ERα-expressing neurons within the vlVMH in lactating mice counteracted these changes. By restoring ERα signaling in this localized neural population, the researchers managed to reduce hyperphagia, lower circulating prolactin levels, and reinstate BAT thermogenesis. This presents a compelling therapeutic angle, suggesting that specific modulation of hypothalamic estrogenic pathways could be harnessed to influence metabolic states in postpartum females, potentially mitigating disorders such as postpartum metabolic syndrome or obesity.

Mechanistically, the study provides fresh insight into how ERα^vlVMH neurons interact within the neuroendocrine axis. The suppression of these neurons removes an inhibitory brake on prolactin secretion, allowing the pituitary gland to ramp up PRL production, thereby sustaining hyperprolactinemia during lactation. Elevated PRL in turn acts peripherally and centrally to drive increased food intake and impair BAT thermogenesis, ensuring energy conservation and allocation toward milk synthesis. These intricately balanced feedback loops exemplify the exquisite hormonal crosstalk orchestrated by the hypothalamus to facilitate the transition into and maintenance of lactational physiology.

Beyond its immediate implications for understanding lactational metabolism, this research opens avenues for exploring estrogenic control mechanisms in broader metabolic disease contexts. ERα signaling in the hypothalamus has emerged as a crucial determinant not only of reproductive behaviors but also of systemic energy balance, implicating it as a possible target in obesity and metabolic dysfunction. The identification of the arcuate nucleus and vlVMH ERα neuronal populations as critical nodes may guide future efforts to develop precision therapeutics that modify hypothalamic estrogenic signaling with minimal off-target effects.

The study’s approach, combining genetic manipulations with detailed phenotypic analyses and cutting-edge neurobiological techniques, sets a new standard for dissecting hormone-brain interactions. Moreover, by honing in on specific neuronal populations within defined hypothalamic subregions, the researchers affirm the concept that even subtle modulations in localized receptor activity can precipitate profound physiological outcomes. This underscores the importance of region-specific interventions in the neuroendocrine realm.

Importantly, the findings challenge previous assumptions that lactational metabolic adaptations stem solely from peripheral hormone changes. Instead, they emphasize the central nervous system’s active role in integrating these signals and executing metabolic shifts. By focusing on ERα^vlVMH neurons, the study reveals a feed-forward mechanism in which estrogenic signaling suppression enables the maintenance of elevated PRL levels, congruent with lactational needs.

The robust hyperprolactinemic phenotype seen upon ERα deletion also brings fresh understanding to the regulation of prolactin itself, a hormone traditionally considered under pituitary control. The demonstration that hypothalamic estrogen receptors directly influence PRL secretion highlights the importance of brain-endocrine axis coordination. This neuroendocrine crosstalk may be fundamental not only in reproductive states but also in pathological conditions marked by dysregulated prolactin, such as prolactinomas or hypothalamic amenorrhea.

Furthermore, the metabolic adaptations observed—specifically the suppression of BAT thermogenesis—shed light on how energy expenditure is strategically modulated during periods of high energy demand like lactation. Since BAT is known to play a key role in adaptive thermogenesis and energy dissipation, its downregulation may be an evolutionary adaptation aimed at conserving energy for the energetically costly process of milk production. The suppression of ERα^vlVMH signaling thus functions as an essential neural switch to enact this physiological state.

By dissecting the balance between E2 and PRL from a hypothalamic perspective, this study also contributes to an improved conceptual framework regarding female energy homeostasis, which is distinctively different from males due to reproductive cycling and states such as pregnancy and lactation. The identification of specific neuroendocrine circuits responsible for this female-specific regulation underlines the importance of sex as a biological variable in metabolic research.

Looking ahead, these findings raise intriguing questions about the potential reversibility of lactation-associated metabolic changes and whether manipulation of hypothalamic estrogen signaling could facilitate the return to pre-pregnancy metabolic states postpartum. Additionally, understanding how external factors such as stress, nutrition, or environmental disruptors impact these circuits during reproductive phases remains an open and vital area of research.

In sum, the suppression of hypothalamic ERα signaling in the MBH emerges as a master regulatory mechanism governing the metabolic phenotype of lactation. This elegant neural adaptation allows hyperprolactinemia to be sustained, driving the mother’s behavioral and physiological shifts to nourish and protect offspring effectively. Unraveling these pathways not only illuminates fundamental aspects of maternal biology but also lays the groundwork for innovative therapeutic strategies targeting hypothalamic estrogenic systems in metabolic and reproductive disorders.

The groundbreaking study by Yu et al., published in Nature Metabolism, provides a compelling blueprint for future investigations into the neuroendocrine control of metabolism and reproductive physiology—a frontier that promises to reshape our understanding of hormone-brain interactions in health and disease.

Subject of Research: Neuroendocrine mechanisms regulating metabolic adaptations during lactation, focusing on estrogen receptor alpha signaling in hypothalamic neurons.

Article Title: Suppression of hypothalamic oestrogenic signal sustains hyperprolactinemia and metabolic adaptation in lactating mice.

Article References:
Yu, M., Feng, B., Bean, J.C. et al. Suppression of hypothalamic oestrogenic signal sustains hyperprolactinemia and metabolic adaptation in lactating mice. Nat Metab 7, 759–777 (2025). https://doi.org/10.1038/s42255-025-01268-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-025-01268-z